A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)
Sponsor: Roche Pharma AG
A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Roche Pharma AG and has accumulated 10 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 5 earlier versions
-
Oct 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roche Pharma AG
- West German Study Group
For direct contact, visit the study record on ClinicalTrials.gov .